Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome.
The effect of intravenous somatostatin infusion was investigated in a patient with severe secretory diarrhea due to malignant carcinoid syndrome. Continuous somatostatin infusion for 48 hr (4 microgram/kg/hr) reduced stool volume from 2.2 to 0.7 liters/day. Intestinal perfusion studies before intravenous somatostatin infusion revealed decreased water and sodium absorption and jejunal chloride secretion. Somatostatin infusion for 2 hr (8 microgram/kg/hr) reversed chloride secretion to absorption and markedly enhanced water and sodium absorption. These results suggest that somatostatin inhibited a secretory component of water and ion movement in the small bowel of the patient with malignant carcinoid syndrome.
D000368:Aged; D003967:Diarrhea / Q000188:drug therapy* / Q000378:metabolism; D004573:Electrolytes / Q000378:metabolism; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007583:Jejunum / Q000187:drug effects*; D008303:Malignant Carcinoid Syndrome / Q000150:complications*; D013004:Somatostatin / Q000627:therapeutic use*; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D004573:Electrolytes; D013004:Somatostatin